Treating Urothelial Bladder Cancer

Preface.- Part I: Bladder cancer diagnosis.- Imaging and bladder cancer: can we do better?.- Optical improvements in bladder cancer diagnosis: seeing better for a better management.- Enhancing the quality of transurethral resection: the importance of a complete TURB and the en-bloc resection.- Active surveillance for low risk non-muscle invasive bladder cancer.- Part II: Non-muscle invasive bladder cancer.- How good we are to predict the outcomes of non-muscle invasive bladder cancer?.- Adjuvant treatment: old and new immunotherapy in non-muscle invasive bladder cancer.- The role of new experimental conservative therapies for high risk non-muscle invasive bladder cancer. Could we trust them?.- Part III: Muscle invasive bladder cancer.- Is there still a role for radical cystectomy?.- Minimally invasive radical cystectomy and its role in the treatment of bladder cancer patients. Myth or reality?.- Neoadjuvant vs adjuvant chemotherapy: which is right?.- Radiotherapy for the treatment of muscle invasive bladder cancer.- Immunotherapy and new combinations.- Part IV: A view on the future.- The role of urologist.- The role of pathologist.- The role of medical oncologist.- The role of radiotherapist.

Paolo Gontero is Associate Professor of Urology at the University of Torino, Italy and currently Chairmen of the Division of Urology, San Giovanni Battista Hospital, Torino, Italy. His main clinical interests are Oncology Urology Surgery, Laparoscopic and Robotic kidney and prostate oncological surgery and Reconstructive Urology. He has authored and co-authored more than 200 publications on international journals.

Francesco Soria is Consultant Urologist at University of Vienna (Urologist, MD, FEBU).

"Each topic is explained clearly, well illustrated, and comprehensively referenced to the current evidence. ... I strongly recommend this book to everyone involved in the care of bladder cancer." (Jay Khastgir, urologynews, urologynews.uk.com, September 1, 2019)